About Us
Company History
Our Mission
Management Team
Board of Directors
Technology
The Problem
The Solution: Our Microbial Platforms
C1
Dapibus™
Advantages and Opportunities
Pipeline
Human Health
Animal Health
Alternative Proteins
Partners
Investors
Overview
Press Releases
SEC Filings
Financials
Investor Fact Sheet
Analyst Coverage
Corporate Governance
Annual Meeting and Proxy
Stock Information
Earnings Calls
Email Alert Opt-in
Media
Articles
Events
Presentations
Press Releases
Scientific Publications
Video Gallery
Contact Us
Snap Quote
Search
Search
Recent Posts
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Dyadic to Present at World Vaccine Congress | Washington
Dyadic Reports 2024 Year-End Financial Results and Business Updates
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
Recent Comments
No comments to show.